These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Role of anthracyclines in the era of targeted therapy. Cortés-Funes H; Coronado C Cardiovasc Toxicol; 2007; 7(2):56-60. PubMed ID: 17652804 [TBL] [Abstract][Full Text] [Related]
24. An introduction to the metabolic determinants of anthracycline cardiotoxicity. Menna P; Recalcati S; Cairo G; Minotti G Cardiovasc Toxicol; 2007; 7(2):80-5. PubMed ID: 17652809 [TBL] [Abstract][Full Text] [Related]
25. Role of mtDNA lesions in anthracycline cardiotoxicity. Lebrecht D; Walker UA Cardiovasc Toxicol; 2007; 7(2):108-13. PubMed ID: 17652814 [TBL] [Abstract][Full Text] [Related]
26. Monitoring of anthracycline cardiotoxicity. Bristow MR; Mason JW; Daniels JR Cancer Treat Rep; 1978 Oct; 62(10):1607-8. PubMed ID: 709565 [No Abstract] [Full Text] [Related]
27. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Gharib MI; Burnett AK Eur J Heart Fail; 2002 Jun; 4(3):235-42. PubMed ID: 12034146 [TBL] [Abstract][Full Text] [Related]
29. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. Jensen BV Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285 [TBL] [Abstract][Full Text] [Related]
30. [Cardiotoxicity of antineoplastic anthracycline antibiotics and prevention by cardioxane (Dexrazoxane) in clinical practice]. Gershanovich ML Vopr Onkol; 2001; 47(1):119-22. PubMed ID: 11317530 [No Abstract] [Full Text] [Related]
31. [Prevention of cardiotoxic effects of anthracyclines in oncopediatric praxis]. Safonova SA; Gershanovich ML; Punanov IuA Vopr Onkol; 2006; 52(5):590-2. PubMed ID: 17168373 [No Abstract] [Full Text] [Related]
32. Cardiotoxicity of cancer chemotherapy: implications for children. Simbre VC; Duffy SA; Dadlani GH; Miller TL; Lipshultz SE Paediatr Drugs; 2005; 7(3):187-202. PubMed ID: 15977964 [TBL] [Abstract][Full Text] [Related]
33. [Cardiac complications of chemotherapy and radiotherapy]. Olive D Arch Fr Pediatr; 1981 May; 38(5):379-84. PubMed ID: 7020629 [No Abstract] [Full Text] [Related]
34. The anthrapyrazoles: a new class of compounds with clinical activity in breast cancer. Judson IR Semin Oncol; 1992 Dec; 19(6):687-94. PubMed ID: 1462167 [TBL] [Abstract][Full Text] [Related]
35. Depression of cardiac function by bisantrene. Artman M; Roloff JS; Olson RD; Parrish MD South Med J; 1985 Dec; 78(12):1517-8. PubMed ID: 3865379 [TBL] [Abstract][Full Text] [Related]
36. Clinical evaluation of the cardiac toxicity of 4'-deoxy-doxorubicin. Villani F; Galimberti M; Comazzi R; Crippa F; Bonfante V; Ferrari L; Pacciarini MA Int J Clin Pharmacol Ther Toxicol; 1988 Apr; 26(4):185-9. PubMed ID: 3403095 [TBL] [Abstract][Full Text] [Related]
37. The role of iron and iron chelators in anthracycline cardiotoxicity. Hershko C; Link G; Tzahor M; Pinson A Leuk Lymphoma; 1993 Oct; 11(3-4):207-14. PubMed ID: 8260895 [TBL] [Abstract][Full Text] [Related]
38. Acute anthracycline cardiotoxicity. Comparative morphologic study of three analogues. Taylor AL; Applefeld MM; Wiernik PH; Grochow LB; Mader LC; Bulkley BH Cancer; 1984 Apr; 53(8):1660-6. PubMed ID: 6582997 [TBL] [Abstract][Full Text] [Related]